isabelobrien, Author at European Medical Journal - Page 47 of 68

Pharma's response to Roe v. Wade

The overturning of Roe v. Wade is impacting access to medical abortion, but in what ways is pharma trying to help?

Roundtable: behind the headlines of Inflation Reduction Act

Two US pricing experts dissect the implications of The Inflation Reduction for the pharma industry in this roundtable.

Cell and gene therapy: a victim of its own success

Landmark science has led to an inundation of new transformative therapies, but is the cell and gene market at the point of saturation?

Following in the footsteps of tech giants

What techniques can pharma companies adopt and adapt from the tech giants dominating the stage of modern-day innovation?

Novartis' Reshema Kemps-Polanco on drive and diversity

What drives Novartis Oncology’s Reshema Kemps-Polanco to succeed?

5 minutes with Anat Cohen-Dayag, CEO, Compugen

Five minutes with Anat Cohen-Dayag, CEO of clinical-stage drug discovery and development company Compugen.

Is the biotech boom on thin ice?

After dizzying heights of investment during the pandemic, biotechs have observed a slump, but the future may look more promising.

Artificially intelligent drug discovery

AI is being implemented into drug development to free up time, money and manpower, but how can humans and computers work together?

Embracing pharma's digital transformation

In his first regular column for GOLD, Davidek Herron discusses digital transformation in pharma and pursuing operational excellence.

An opportunity to crack the opioid crisis

With opioid abuse showing little sign of abating, what role can pharma play in addressing the crisis?